Clinical Trial

Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this clinical research study is to study the recommended dose of TROP2 CAR/IL-15 TGFBR2 KO NK cells that can be given intraperitoneally (infused directly into the stomach area) to participants with adenocarcinoma of the stomach that has spread to the peritoneum. The safety and effectiveness of this treatment will also be studied.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-30.
Trial Details
NCT Number NCT07509008
Lead Sponsor M.D. Anderson Cancer Center
Conditions Gastric Cancer, Metastatic
Enrollment 10 participants
Start Date 2026-09-01
Primary Completion 2028-07-01 (estimated)
Study Completion 2030-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-29